Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Ecolab Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.32 (market cap $863.95M), while Ecolab Inc. trades at $284.2 (market cap $79.73B). The key difference: Ecolab Inc. is far larger — about 92.3× Amphastar Pharmaceuticals Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ECL | |
|---|---|---|
Market Cap | $863.95M | $79.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $308.35 |
52-Week Low | $16.87 | $245.73 |
Enterprise Value | $1.26B | $88.51B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ECL trades at $285.17, up 0.6% today, with a bullish technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 12.57% and robust cash flow from operations of $2.95B in 2025. Recent news highlights dividend declarations and institutional buying interest.
Outlook is positive with a consensus price target of $327.90, implying 15% upside. Risks include elevated valuation multiples and potential margin pressure from input costs. The stock's momentum is supported by earnings beats and strategic acquisitions, but investors should monitor debt levels and competitive dynamics in the water and hygiene sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
